TGI-17b / TG ImmunoPharma - LARVOL DELTA

TGI-17b: A potential first-in-class PD-1/VEGF/IL-2α-bias trispecific antibody and the potential next generation cornerstone for pan-cancer therapy (AACR 2026) - "In functional assays, TGI-17b blocked PD-1/PD-L1 interaction with a slightly higher EC50, and blocked VEGF/VEGFR1 and VEGF/VEGFR2 interactions with significantly lower EC50 values compared to AK112, a PD-1/VEGF bispecific antibody (PD-1/PD-L1 blockade EC50: 0.70 µg/mL for TGI-17b vs. 0.32 µg/mL for AK112; VEGF/VEGFR1 blockade EC50: 0.37 µg/mL vs. 3.53 µg/mL; VEGF/VEGFR2 blockade EC50: 1.29 µg/mL vs. 7.71 µg/mL). These results indicate that TGI-17b, a potential first-in-class PD-1/VEGF/IL-2α-bias trispecific antibody, possesses compelling anti-tumor efficacy and a favorable safety profile in preclinical models. This robust evidence supports its further clinical development as a promising therapeutic candidate for pan-cancer applications."

Pan tumor • Trispecific • Oncology • Solid Tumor • FLT1 • PD-1